Key facts
- It has raised $15.0M; the latest was Early Stage VC in Feb 2025.
- Notable investors include Hongshan Capital Group, F-Prime Capital, Eight Roads, XtalPi Technology.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Alternative Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Alternative Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alternative Bio
Provider and developer of drugs designed for tumors. The company focuses on protein synthesis, enabling patients with treatments.
- Sector
- Healthcare
- HQ
- Hong Kong, Hong Kong
- Founded
- 2022
- Ownership
- Privately Held (backing)
Alternative Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alternative Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alternative Bio in its N-PORT filings yet. We sweep new filings monthly.